Turgut Ilaclari and Selexis link up for biosimilars development

Swiss biotech firm Selexis and Turgut Ilaclari, a leading biosimilar developer based in Turkey, have entered into a service agreement that provides Turgut with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of quality biosimilar products for the treatment of inflammatory diseases, certain cancers and two rare diseases.

“Our scientists, inspired by the innovation of our technology, are driven to provide high performance, cost-effective solutions to companies, such as Turgut, for therapeutic protein production,” said Marco Bocci, Selexis vice president, licensing and business development., adding: “We are pleased to report excellent progress on this project, recently completing two of the five cell lines. Partnerships are fundamental to our success, and we look forward to continuing our long-term relationship with Turgut.”

Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.